ArticleRespiratory research2026
Quantitative computed tomography body composition analysis for risk stratification in bronchiectasis.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNutritional status and sarcopenia are established contributors to morbidity and mortality in chronic respiratory diseases. This study aimed to assess the prevalence and impact of body composition features extracted from computed tomography (CT) in patients with non-CF bronchiectasis.
methodsWe analysed data from 112 patients. Muscle and subcutaneous fat area and density were assessed by semi-automatic segmentation at the level of the 12th thoracic vertebra using the mediastinal window of routine chest CT scans. Clinical and functional features were compared between patients with and without body composition abnormalities. Associations between CT-derived body composition parameters and clinical outcomes were explored.
resultsThe majority of patients were female (86/112, 77%) and the median age was 66 years (56–74). Myosteatosis (low muscle density) affected 75 of 112 (66%) patients. Patients with myosteatosis (MSp) were older than those without (wMSp), median age 70 (61–77) vs. 58 (45–69) years (p < 0.001), and had lower FEV1, 81 (69–95) vs. 89 (78–101) % pred. (p = 0.038) and MEF50, 48 (25–66) vs. 61 (44–74) % pred. (p = 0.043). The incidence of non-tuberculous mycobacteria (NTM) pulmonary disease was higher in MSp compared to wMSp (19% vs. 3%; p = 0.043). Muscular density negatively correlated with the Bronchiectasis Severity Index (r = − 0.32; p = 0.012), FACED (r = − 0.38; p = 0.03) and E-FACED (r = − 0.35; p = 0.007) scores. Myosteatosis was not related to gender, radiological extension of bronchiectasis, bacterial colonization or laboratory data.
conclusionsMyosteatosis is highly prevalent in patients with bronchiectasis and is associated with worse airflow obstruction, higher disease severity, and increased frequency of NTM pulmonary disease, independently from BMI. Abnormal body composition as defined by CT assessment may provide clinically relevant information beyond traditional anthropometrics and complement existing severity scores for risk stratification in patients with bronchiectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.